Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cance (Q74276899)
Jump to navigation
Jump to search
scientific article published on 01 January 1998
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cance |
scientific article published on 01 January 1998 |
Statements
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group (English)
R Paridaens
J A Roy
M Nooij
J Klijn
S J Houston
L V Beex
J Vinholes
E Tomiak
A Van Vreckem
C Langenaeken
M Van Glabbeke